OCREVUS: payments to doctors
Payments that named OCREVUS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $95M
- Providers
- 7,597
- Transactions
- 59,688
- Average per transaction
- $1,592
The per-transaction average — $1,592 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,597 providers the average total is $12,505, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $79,776,782 | 84.0% |
| Genentech USA, Inc. | $14,283,407 | 15.0% |
| F. Hoffmann-la Roche AG | $699,535 | 0.7% |
| Roche Products Limited | $142,854 | 0.2% |
| Hoffmann-la Roche Limited | $94,940 | 0.1% |